Apellis Pharmaceuticals, Inc.
APLS
$17.49
-$0.05-0.29%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 36.72% | -52.55% | 43.31% | 25.01% | 36.84% |
| Total Depreciation and Amortization | -2.19% | 1.78% | 1.13% | -6.72% | 3.03% |
| Total Amortization of Deferred Charges | -10.79% | 176.47% | 213.16% | 1.33% | 0.00% |
| Total Other Non-Cash Items | -4.23% | -21.07% | -4.41% | 11.39% | 16.05% |
| Change in Net Operating Assets | -54.94% | 1,118.95% | 94.03% | -143.28% | 26.09% |
| Cash from Operations | -43.22% | 508.87% | 93.73% | -35.87% | 42.11% |
| Capital Expenditure | -- | 100.00% | 69.28% | -208.42% | -102.13% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 100.00% | 69.28% | -7,425.00% | 108.51% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | 200.00% | -- | -- | -- |
| Issuance of Common Stock | -35.84% | -50.42% | -45.61% | -65.02% | 370.54% |
| Repurchase of Common Stock | -7.14% | -- | 100.00% | -1,300.00% | 81.82% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -254.00% | 99.51% | -430.62% | 418.59% | -- |
| Cash from Financing | -257.36% | -94.02% | -60.74% | 2,865.45% | -168.10% |
| Foreign Exchange rate Adjustments | -657.80% | -49.42% | 263.64% | -135.79% | 227.51% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -60.95% | 7.01% | 236.11% | 75.03% | 38.23% |